ABVC Biopharma Inc
NASDAQ:ABVC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ABVC Biopharma Inc
NASDAQ:ABVC
|
US |
|
Vmoto Ltd
ASX:VMT
|
AU |
|
Adidas AG
XETRA:ADS
|
DE |
|
H
|
Hyungkuk F&B Co Ltd
KOSDAQ:189980
|
KR |
|
Telus Corp
TSX:T
|
CA |
|
P
|
PJ Electronics Co Ltd
KOSDAQ:006140
|
KR |
|
C
|
Century Global Commodities Corp
TSX:CNT
|
HK |
|
J
|
Janone Inc
F:5AR1
|
US |
|
G-Tec Jainx Education Ltd
NSE:GTECJAINX
|
IN |
|
G
|
GBK Beteiligungen AG
XHAM:GBQ
|
DE |
|
B2Gold Corp
TSX:BTO
|
CA |
ABVC Biopharma Inc
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
ABVC BioPharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development of new drugs and medical devices. The company is headquartered in Fremont, California and currently employs 28 full-time employees. The company went IPO on 2004-11-09. The firm develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. Its pipeline includes ABV-1501, ABV-1504, ABV-1505, ABV-1703, ABV-1601, ABV-1701 and ABV-2002. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). The company is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). The company has developed ABV-1601 for treating depression in cancer patients. ABV-1501 is a combination therapy for triple negative breast cancer (TNBC). ABV-1701 is a vitreous substitute for vitrectomy. ABV-1703 is a drug for advanced inoperable or metastatic pancreatic cancer. ABV-2002 is a corneal storage media consisting of a specific polymer formulated to protect ocular tissues from osmolarity.
